Natera Launches Fetal Focus Noninvasive Prenatal Test for Inherited Conditions
The new noninvasive prenatal test addresses testing gaps when biological fathers are unavailable for carrier screening by analyzing fetal DNA from maternal blood samples.
The new noninvasive prenatal test addresses testing gaps when biological fathers are unavailable for carrier screening by analyzing fetal DNA from maternal blood samples.
Measuring reproductive health is becoming more exacting as medical technology advances. One of the newest ways is with cytogenetics analysis.
Premier Medical Laboratory Services has added Noninvasive Prenatal Testing to its line of diagnostic testing and risk screening services.
Half of pregnant women who had a simple blood test to check their iron stores had low iron levels; one in four had severe iron deficiency.
Read MorePreciseMDX introduces a cloud-based solution that automates and simplifies the diagnostic testing experience.
Read MoreBioReference Laboratories, Inc. has acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche.
Read MoreAs part of the agreement, EchelonDx is providing expertise using its precise PrenatalDx technology to help enhance the data analysis and reporting capabilities for Cradle’s comprehensive fetal genetic analysis and health screening solutions.
Read MoreThe method uses a DNA biomarker to easily screen pregnant women for harmful prenatal environmental contaminants like air pollution linked to childhood illness and developmental disorders.
Read MoreThe new CPT PLA code will facilitate billing and payment for the PreTRM Test, the company’s proprietary proteomic blood test for measuring a woman’s risk of spontaneous preterm birth to enable timely intervention.
Read MoreThe PRIME study is designed to provide a blueprint for how healthcare can more effectively identify and manage high-risk pregnancies and reduce preterm birth.
Read MoreA new study outlines a role for pregnancy-associated plasma protein A in gestational diabetes, with potential as a diagnostic tool and therapeutic target.
Read MoreThis proprietary test is a multi-analyte protein biomarker assay which is designed to be run from a simple blood draw.
Read MoreA blood test commonly used to detect fetal genetic abnormalities can be modified to help predict complications associated with pregnancy before any symptoms develop, according to UCLA researchers and colleagues.
Read MoreThe Amplify process increases the fetal fraction of a NIPS sample by preferentially sequencing the fetal cell-free DNA fragments that circulate in a mother’s blood.
Read MoreThe test broadens expectant parents’ prenatal testing options to include a safe, noninvasive test tailored to their family’s risk for a specific genetic disease.
Read MoreThe Foresight carrier screen identified 45% more couples at risk for having a child with cystic fibrosis than current guideline-based testing.
Read MoreEnhanced test improves detection of chromosomal abnormalities by 30%.
Read MoreThe Parsortix system offers the potential to extend NIPT to a wide range of conditions not feasible with existing techniques.
Read More